Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in pat… Read more
Tscan Therapeutics Inc (TCRX) - Net Assets
Latest net assets as of September 2025: $144.02 Million USD
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has net assets worth $144.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($262.23 Million) and total liabilities ($118.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $144.02 Million |
| % of Total Assets | 54.92% |
| Annual Growth Rate | 41.44% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 104.43 |
Tscan Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Tscan Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tscan Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Tscan Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $240.97 Million | +59.72% |
| 2023-12-31 | $150.87 Million | +51.73% |
| 2022-12-31 | $99.43 Million | -38.15% |
| 2021-12-31 | $160.78 Million | +478.64% |
| 2020-12-31 | $-42.46 Million | -199.81% |
| 2019-12-31 | $42.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tscan Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35769000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $51.00K | 0.02% |
| Other Components | $616.01 Million | 255.64% |
| Total Equity | $240.97 Million | 100.00% |
Tscan Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tscan Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
E3 LITHIUM LTD
F:OW3
|
$51.36 Million |
|
GrandTech C.G. Systems
TWO:6123
|
$51.38 Million |
|
New Ulm Telecom Inc
OTCQB:NUVR
|
$51.40 Million |
|
Alarum Technologies Ltd.
NASDAQ:ALAR
|
$51.43 Million |
|
Tureks Turizm Tasimacilik AS
IS:TUREX
|
$51.35 Million |
|
Tradetool Auto Co Ltd
TWO:3685
|
$51.35 Million |
|
Serviceware SE
F:SJJ
|
$51.33 Million |
|
Kaset Thai International Sugar Corporation Public Company Limited
BK:KTIS
|
$51.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tscan Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 150,867,000 to 240,970,000, a change of 90,103,000 (59.7%).
- Net loss of 127,499,000 reduced equity.
- New share issuances of 33,131,000 increased equity.
- Other comprehensive income increased equity by 51,000.
- Other factors increased equity by 184,420,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-127.50 Million | -52.91% |
| Share Issuances | $33.13 Million | +13.75% |
| Other Comprehensive Income | $51.00K | +0.02% |
| Other Changes | $184.42 Million | +76.53% |
| Total Change | $- | 59.72% |
Book Value vs Market Value Analysis
This analysis compares Tscan Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.51x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.64x to 0.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.71 | $1.09 | x |
| 2020-12-31 | $-1.70 | $1.09 | x |
| 2021-12-31 | $6.72 | $1.09 | x |
| 2022-12-31 | $4.13 | $1.09 | x |
| 2023-12-31 | $2.30 | $1.09 | x |
| 2024-12-31 | $2.15 | $1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tscan Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4527.66%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.54x
- Recent ROE (-52.91%) is below the historical average (-40.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -32.10% | 0.00% | 0.00x | 1.16x | $-17.91 Million |
| 2020 | 0.00% | -2408.02% | 0.02x | 0.00x | $-21.88 Million |
| 2021 | -30.24% | -479.49% | 0.05x | 1.17x | $-64.70 Million |
| 2022 | -66.60% | -489.26% | 0.07x | 2.00x | $-76.16 Million |
| 2023 | -59.14% | -423.86% | 0.08x | 1.80x | $-104.30 Million |
| 2024 | -52.91% | -4527.66% | 0.01x | 1.54x | $-151.60 Million |
Industry Comparison
This section compares Tscan Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tscan Therapeutics Inc (TCRX) | $144.02 Million | -32.10% | 0.82x | $51.36 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |